• Corpus ID: 30276048

Antihelminthic drugs as a treatment for hyperproliferative diseases

@inproceedings{Liss2012AntihelminthicDA,
  title={Antihelminthic drugs as a treatment for hyperproliferative diseases},
  author={Alan R. Liss},
  year={2012}
}

• A. Liss
• Published 2012
• Biology

1These drugs can be combined with conventional chemotherapeutics such as cisplatin, carboplatin, adriamycin, taxol etc. and enhance tumor cell killing. 2Cytotoxic effects: binding to the microtubule system and disrupting its functions 3Induction of Nuclear Accumulation of p53 : Both FZ and MZ showed an apoptotic effect on the H460 cells 4Increased Half-Life of p53 in Drug-Treated Cells 5Selective Induction of Apoptosis by Fenbendazole and Mebendazole in Tumor Cells Carrying Wild-Type p53 6BZ-Induced Apoptosis in Human several human cancer 7The starting dose will be 0.1 to 1 mg BZ/kg body weight.BZ=Benzimidazol 8Alternative dosing regimens will use administration of BZ on alternate days, or twice or one per week. Cumulative doses can be up to 2000-3000 mg, given either in bolus administrations over 2-3 days or in divided doses over a longer timeperiod, ranging from 1 week to 2-4, 4-8, 8-12, 12-16 weeks. 9Methyl 5-benzoylbenzimidazole-2-carbamate (Mebendazole (MZ)) and methy 5(phenylthio)-2-benzimidazole-2-carbamate (Fenbendazole (FZ)) were purchased from Sigma Chemical Company (St. Louis, Mo.): In vitro studies